Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adenocarcinoma
Scientists at Centre Hospitalier Lyon Sud detail research in adenocarcinoma
June 17th, 2008
According to recent research from Pavillon, France, "The aim of the present investigation was to evaluate the prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) tissue contents in primary breast adenocarcinoma. Patients from 3 medical centers were included between 1994 and 2001." "Biologic factors in tumor extracts were all assayed in the some laboratory. PAI-1 and uPA were treated as continuous or dichotomized variables. Metastasis-free survival analyses were performed using the Cox model and the classification algorithm and regression tree (CART) in the whole population and in the subsets of...
Source: Cancer Weekly (2008-06-17)
|
